# EDGAR Filing Document

**Accession Number:** 0000034956
**File Stem:** 0001654954-26-002112
**Filing Date:** 2026-3
**Character Count:** 8446
**Document Hash:** 217db1968a3c2fc8c5c8df8dfc6a5b86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-002112.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001654954-26-002112

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TENAX THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0000034956
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262593535
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-58467
- **FILM NUMBER:** 26740844

**BUSINESS ADDRESS:**
- **STREET 1:** 101 GLEN LENNOX DRIVE
- **STREET 2:** SUITE 300
- **CITY:** CHAPEL HILL
- **STATE:** NC
- **ZIP:** 27517
- **BUSINESS PHONE:** 919-855-2100

**MAIL ADDRESS:**
- **STREET 1:** 101 GLEN LENNOX DRIVE
- **STREET 2:** SUITE 300
- **CITY:** CHAPEL HILL
- **STATE:** NC
- **ZIP:** 27517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OXYGEN BIOTHERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20080703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SYNTHETIC BLOOD INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SINEQUANON CORP
- **DATE OF NAME CHANGE:** 19901219
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Giordano Christopher Thomas
- **CENTRAL INDEX KEY:** 0001871714

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O TENAX THERAPEUTICS, INC.
- **STREET 2:** ONE COPLEY PARKWAY, SUITE 490
- **CITY:** MORRISVILLE
- **STATE:** NC
- **ZIP:** 27560

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Giordano Chrisopher Thomas
- **DATE OF NAME CHANGE:** 20210708

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**TENAX THERAPEUTICS, INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**88032L605**

*(CUSIP Number)*

**Christopher Thomas Giordano**<br>c/o Tenax Therapeutics, Inc.<br>101 Glen Lennox Drive, Suite 300<br>Chapel Hill NC 27517<br>919-855-2100

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **88032L605** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Christopher Thomas Giordano** | Name of reporting person<br>**Christopher Thomas Giordano** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1252965.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1252965.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1252965.00** | Aggregate amount beneficially owned by each reporting person<br>**1252965.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.79%** | Percent of class represented by amount in Row (11)<br>**6.79%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The percentage reported above is based on 17,197,613 shares of the Issuer's common stock (the "Common Stock") outstanding as of March 6, 2026, as reported in the Issuer's Form 10-K ("Form 10-K") filed with the SEC on March 10, 2026 and is calculated on a beneficial ownership basis.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
TENAX THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
101 Glen Lennox Drive, Suite 300, Chapel Hill,, NC, 27517

This Schedule 13D is being filed to show Mr. Giordano's beneficial ownership of the Issuer's Common Stock as of the filing date.

**Item 4. Purpose of Transaction**

Mr. Giordano has acquired, and holds, the shares of Common Stock reported herein for investment purposes. He may acquire additional shares of Common Stock depending on market conditions and the business performance of the Issuer, but does not currently plan to purchase a number of additional shares of Common Stock that would result in a substantial change in his beneficial ownership or his ability to influence control of the Issuer.
 
 Other than as described above, and except that Mr. Giordano may, from time to time or at any time, subject to market conditions and other factors, purchase additional shares of Common Stock in the open market, in privately negotiated transactions or otherwise, sell at any time all or a portion of the shares of Common Stock now owned or hereafter acquired by him to one or more purchasers, or transfer or contribute shares of Common Stock to trusts for estate planning purposes, Mr. Giordano does not have any present plans which relate to or would result in:
  
 (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;
  
 (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or
 any of its subsidiaries;
  
 (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;
  
 (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to
  change the number or term of directors or to fill any existing vacancies on the board;
  
 (e) any material change in the present capitalization or dividend policy of the Issuer;
  
 (f) any other material change in the Issuer's business or corporate structure;
  
 (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may 
 impede the acquisition of control of the Issuer by any person;
  
 (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be 
 authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
  
 (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section
 12(g)(4) of the Exchange Act; or
  
 (j) any action similar to any of those actions enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
1,252,965 - 6.79%

**(b)**
1,252,965

**(c)**
Reference is made to the discussion in Item 3.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Information set forth in Item 3 is incorporated herein by reference.  Mr. Giordano may in the future receive additional grants of equity awards as compensation for serving as the Issuer's President and Chief Executive Officer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Christopher Thomas Giordano

**Signature:** /s/ Christopher Thomas Giordano

**Name/Title:** President and Chief Executive Officer

**Date:** 03/10/2026